Clinical Trial Update: Increasing Ureagenesis in Inborn Errors of Metabolism With N-Carbamylglutamate [Phase 2]

View source ↗

Summary

Phase 2 trial of N-Carbamylglutamate to increase ureagenesis in urea cycle disorders and other inborn errors of metabolism has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carbamoyl Phosphate Synthetase Deficiency
• Inborn Errors of Metabolism
• Methylmalonic Acidemia
• Propionic Acidemia
• Urea Cycle Disorders

Drugs mentioned

• N-Carbamylglutamate (N-carbamylglutamate)

Snippet

Sponsor: Children's Hospital of Philadelphia | Conditions: Urea Cycle Disorders, Inborn, Inborn Errors of Metabolism | Phase 2 | Status: WITHDRAWN